Stock 688621 BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Equities

688621

CNE100005139

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 30/06/2024 BST 		5-day change 1st Jan Change
43 CNY +0.70% Intraday chart for Beijing Sun-Novo Pharmaceutical Research Co., Ltd. -3.59% -38.35%
04-25 Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-26 Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(XSSC:688621) added to S&P Global BMI Index
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Beijing Langyan Life Technology Holdings Co., Ltd. from a group of shareholders.
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches
MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sun-Novo Pharma Unit Gets Drug Regulator's Certification for Desmopressin Injection
MT
Sun-Novo Pharma Unit to Set Up 10 Million Joint Venture With Midea Pharma
MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding
CI
Sun-Novo Pharma Logs 49.8% Jump in 2022 Profit
MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Sun-Novo Pharmaceutical Purchases Azilsartan Tablets’ Marketing Rights For $5 Million
MT
Beijing Sun-Novo Gets Regulatory Approval in China For Anti-Dermatitis Cream
MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. agreed to acquire Beijing Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership), Liu Yujing and other shareholders.
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange Composite Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688621 Stock
  4. News Beijing Sun-Novo Pharmaceutical Research Co., Ltd.